Mymetics Corporation (MYMX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mymetics Corporation (MYMX) trades at $0.0003 with AI Score 47/100 (Grade C). Mymetics Corporation is a Swiss vaccine company focused on developing vaccines for infectious diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for MYMX: MYMX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MYMX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MYMX: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Mymetics Corporation (MYMX) Healthcare & Pipeline Overview
Mymetics Corporation, a Swiss biotechnology company founded in 1990, specializes in the research and development of virosome-based vaccines targeting infectious and life-disabling diseases. With a diverse product pipeline including HIV-1/AIDS and malaria, the company operates in a competitive landscape, collaborating with research institutions and pharmaceutical companies to advance its vaccine candidates.
What Is the Investment Thesis for MYMX?
Mymetics Corporation presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on virosome-based vaccine development for diseases like HIV-1/AIDS and malaria addresses significant unmet medical needs. However, the company's small market capitalization and negative profitability highlight its dependence on successful clinical trials and future partnerships. Key value drivers include the advancement of its vaccine candidates through clinical trials and securing partnerships with larger pharmaceutical companies. The success of these vaccines could lead to substantial revenue generation and increased market capitalization. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies with greater resources. Investors should closely monitor the progress of Mymetics' clinical trials and partnership developments to assess the company's potential for long-term growth.
Based on FMP financials and quantitative analysis
MYMX Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.02 reflects the company's current lack of profitability.
- Profit margin of -160166.7% indicates substantial losses relative to revenue.
- Gross margin of -47966.7% suggests high cost of goods sold or significant research and development expenses.
- Beta of 2.29 indicates higher volatility compared to the overall market, reflecting the speculative nature of biotechnology stocks.
Who Are MYMX's Competitors?
MYMX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MYMX's Key Strengths?
Virosome-based vaccine technology platform.
- Diverse vaccine pipeline targeting multiple infectious diseases.
- Collaborative partnerships with research institutions.
- Focus on addressing unmet medical needs.
What Are MYMX's Weaknesses?
Limited financial resources.
- Small number of employees.
- Dependence on successful clinical trials.
- Lack of commercialized products.
What Could Drive MYMX Stock Higher?
Clinical trial results for HIV-1/AIDS vaccine candidate.
- Partnership announcements with pharmaceutical companies.
- Regulatory submissions for vaccine approvals.
- Research and development progress on malaria vaccine.
- Collaboration with Sanofi Pasteur Biologics on influenza vaccine.
What Are the Key Risks for MYMX?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for vaccine candidates.
- Regulatory delays or rejections.
- Competition from established pharmaceutical companies.
- Limited financial resources.
- Dependence on successful partnerships.
What Are the Growth Opportunities for MYMX?
- Advancement of HIV-1/AIDS Vaccine Candidate: The global HIV vaccine market represents a significant opportunity. According to UNAIDS, approximately 39 million people were living with HIV in 2022. Successful development and commercialization of an effective HIV vaccine could generate substantial revenue for Mymetics. The timeline for this growth opportunity depends on the successful completion of clinical trials, which could take several years.
- Development of Malaria Vaccine: Malaria remains a major global health challenge, particularly in developing countries. Mymetics' collaboration with the PATH Malaria Vaccine Initiative and other research institutions positions it to potentially develop a transmission-blocking malaria vaccine. The global malaria vaccine market is projected to grow, driven by the need for effective prevention strategies. Clinical trials and regulatory approvals will determine the timeline for this opportunity.
- Expansion of Influenza Vaccine Portfolio: Mymetics is exploring the immunogenicity of influenza vaccines through a collaboration with Sanofi Pasteur Biologics, LLC. The seasonal influenza vaccine market is well-established, but there is a continuous need for improved vaccines with broader protection and enhanced efficacy. Mymetics' virosome-based technology could offer advantages in this area. The timeline depends on the results of ongoing research and development efforts.
- Commercialization of Covid-19 Vaccine: While the initial surge in demand for Covid-19 vaccines has subsided, there remains a need for updated vaccines that address emerging variants. Mymetics' Covid-19 vaccine candidate could potentially address this need, particularly if it demonstrates superior efficacy or safety compared to existing vaccines. The timeline for this opportunity depends on the evolving dynamics of the pandemic and the regulatory approval process.
- Partnerships and Licensing Agreements: Mymetics can pursue growth by forming strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its vaccine candidates. Licensing agreements can provide upfront payments, milestone payments, and royalties, generating revenue and validating the company's technology. The timeline for this growth opportunity depends on Mymetics' ability to attract and secure favorable partnership agreements.
What Are MYMX's Competitive Advantages?
- Virosome-based vaccine technology platform.
- Collaborative partnerships with research institutions and pharmaceutical companies.
- Intellectual property protection for its vaccine candidates.
- Focus on addressing unmet medical needs in infectious diseases.
What Does MYMX Do?
Mymetics Corporation, originally named ICHOR Corporation, was founded in 1990 and rebranded in July 2001. Headquartered in Epalinges, Switzerland, the company is dedicated to the research and development of innovative vaccines designed to combat infectious and life-disabling diseases. Mymetics employs a virosome-based technology platform to develop its vaccine candidates. The company's product pipeline encompasses a range of vaccines targeting critical global health challenges, including HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. Mymetics actively engages in collaborative partnerships to advance its research and development efforts. These collaborations include agreements with the Texas Biomedical Research Institute, PATH Malaria Vaccine Initiative, and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases, focusing on the development of virosome-based vaccine formulations for a malaria transmission-blocking vaccine candidate. Additionally, Mymetics collaborates with Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. Mymetics operates within the biotechnology sector, focusing on preventative medicine through vaccine development. The company's strategy involves both internal research and external collaborations to expand its pipeline and accelerate the development of its vaccine candidates.
What Products and Services Does MYMX Offer?
- Researches and develops vaccines for infectious diseases.
- Focuses on virosome-based vaccine technology.
- Develops vaccine candidates for HIV-1/AIDS.
- Develops vaccine candidates for Covid-19.
- Develops vaccine candidates for influenza.
- Develops vaccine candidates for respiratory syncytial virus (RSV).
- Develops vaccine candidates for malaria.
- Develops vaccine candidates for chikungunya.
How Does MYMX Make Money?
- Develops vaccine candidates through internal research and development.
- Collaborates with research institutions and pharmaceutical companies.
- Seeks partnerships and licensing agreements to commercialize its vaccines.
- Generates revenue through grants, partnerships, and potential future vaccine sales.
What Industry Does MYMX Operate In?
Mymetics Corporation operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Mymetics focuses on virosome-based vaccines, a technology that offers potential advantages in terms of immunogenicity and safety. The company competes with larger pharmaceutical companies and specialized biotechnology firms, requiring strategic partnerships and successful clinical trials to gain market share.
Who Are MYMX's Key Customers?
- Governmental health organizations (e.g., WHO, national health ministries).
- Non-profit organizations focused on global health (e.g., PATH, Bill & Melinda Gates Foundation).
- Pharmaceutical companies seeking to expand their vaccine portfolios.
- Patients in need of preventative vaccines.
Key Financial Metrics
Return on equity for Mymetics Corporation stands at 7.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -65.6%, showing how much profit it generates from its asset base. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Mymetics Corporation (MYMX) Valuation Context
Relative to its peer group, MYMX's quantitative score of 47/100 is below the peer average of 76/100.
Company Profile
Mymetics Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Epalinges, CH. The company is led by CEO Ronald Kempers. MYMX has traded publicly since 1999.
Financial Health
Mymetics Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
MYMX Financials
Bull Case vs Bear Case
Bull Case
- Virosome-based vaccine technology platform.
- Diverse vaccine pipeline targeting multiple infectious diseases.
- Collaborative partnerships with research institutions.
- Focus on addressing unmet medical needs.
Bear Case
- Limited financial resources.
- Small number of employees.
- Dependence on successful clinical trials.
- Lack of commercialized products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
MYMX Latest News
No recent news available for MYMX.
MYMX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MYMX.
Price Targets
Wall Street price target analysis for MYMX.
MYMX MoonshotScore
What does this score mean?
The MoonshotScore rates MYMX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ronald Kempers
Unknown
Information about Ronald Kempers' background is not available in the provided data. His career history, education, and previous roles are unknown. Based on the provided data, he is currently managing 2 employees at Mymetics Corporation.
Track Record: Information about Ronald Kempers' track record is not available in the provided data. Key achievements, strategic decisions, and company milestones under his leadership are unknown.
MYMX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Mymetics Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, may be thinly traded, and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Lack of transparency due to potentially limited financial reporting.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Potential for delisting or suspension of trading.
- Limited access to company information and management.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's capital structure and debt levels.
- Understand the company's regulatory environment and compliance requirements.
- Consult with a qualified financial advisor.
- Collaborative partnerships with reputable research institutions.
- Focus on developing vaccines for significant global health challenges.
- History of research and development activities.
- Presence of intellectual property protection (patents).
- Company is registered in Switzerland.
What Investors Ask About Mymetics Corporation (MYMX) — Healthcare
What does the AI Score mean for MYMX?
MYMX holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Mymetics Corporation is a Swiss vaccine company focused on developing vaccines for infectious diseases. Their pipeline includes vaccine candidates for HIV-1/AIDS, Covid-19, influenza, RSV, malaria …
What does Mymetics Corporation do?
Mymetics Corporation is a Swiss biotechnology company focused on the research and development of virosome-based vaccines for infectious and life-disabling diseases. The company's product pipeline includes vaccine candidates for HIV-1/AIDS, Covid-19, influenza, RSV, malaria, and chikungunya. Mymetics collaborates with research institutions and pharmaceutical companies to advance its vaccine candidates through preclinical and clinical development, aiming to address significant unmet medical needs in global health.
What do analysts say about MYMX stock?
As of March 16, 2026, there is no available analyst coverage or consensus for Mymetics Corporation (MYMX). The company's small market capitalization and OTC listing may limit analyst interest. Investors should conduct their own due diligence and consider the company's financial performance, clinical trial progress, and partnership developments when evaluating MYMX. Key valuation metrics are difficult to assess due to the company's negative profitability.
What are the main risks for MYMX?
Mymetics Corporation faces several key risks inherent to the biotechnology industry and its specific circumstances. Clinical trial failures represent a significant risk, as the success of its vaccine candidates is crucial for future revenue generation. Regulatory hurdles and delays in obtaining approvals can also impact the company's timeline and financial performance.
What are the key factors to evaluate for MYMX?
Mymetics Corporation (MYMX) holds an AI score of 47/100 (low). Mymetics Corporation presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does MYMX data refresh on this page?
MYMX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MYMX's recent stock price performance?
Mymetics Corporation (MYMX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Virosome-based vaccine technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MYMX overvalued or undervalued right now?
Mymetics Corporation (MYMX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MYMX before investing?
Before investing in Mymetics Corporation (MYMX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC market data may be less reliable than major exchanges.
- CEO information is incomplete.